Feasibility and Safety of a Portable Exoskeleton to Improve Mobility in Parkinson’s Disease
便携式外骨骼改善帕金森病患者活动能力的可行性和安全性
基本信息
- 批准号:10702193
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-10-01 至 2025-09-30
- 项目状态:未结题
- 来源:
- 关键词:Activities of Daily LivingAdverse eventAgingAlabamaAmputationBilateralBody HeightBody WeightBrainCanesCaregiversCharacteristicsChronic Obstructive Pulmonary DiseaseClinicClinical ResearchClinical TrialsCollaborationsCrutchesDataDeep Brain StimulationDementiaDevicesDisabled PersonsDiseaseEffectivenessEnteral FeedingEquilibriumExclusion CriteriaExerciseExertionFogsFreezingFundingFutureGaitGoalsGrantHandHomeHypotensivesImpaired cognitionImpairmentIndividualInterventionInvestigationLeadershipLegLevodopaLifeLife StyleLower ExtremityMeasuresMedical centerModalityModernizationMovement Disorder Society Unified Parkinson&aposs Disease Rating ScaleMovement DisordersMulti-Institutional Clinical TrialMulti-site clinical studyMusculoskeletalNervous System TraumaNeurologicNeurologyNoseOperative Surgical ProceduresOrthostasisOrthostatic HypotensionOutcomePainParalysedParaplegiaParkinson DiseaseParkinsonian DisordersPatientsPersonsPharmaceutical PreparationsPhysical ExercisePhysical therapyPilot ProjectsPopulationPositioning AttributePostureProductivityQualifyingQuality of lifeQuestionnairesRecording of previous eventsRehabilitation therapyResearchResearch PersonnelResistanceRoboticsRoleRunningSafetySamplingSeasonsSelf-Help DevicesSeveritiesSeverity of illnessSkin injurySpecialistStrokeSupervisionSymptomsTechnologyTestingTherapeuticTherapeutic InterventionTrainingTreatment EfficacyUniversitiesVeteransVirginiaVisitWalkingWheelchairsWorkcardiac devicecardiac implantclinical centercognitive testingdesigndisabilityexercise trainingexoskeletonexoskeleton deviceexperiencefallsgait rehabilitationimproved mobilityinclusion criteriaindependent ambulationlight weightmobility aidmusculoskeletal injuryparticipant interviewphysical therapistportabilityprimary endpointrecruitresearch and developmentresistance exercisesafety and feasibilitysafety assessmentskin irritationstandard of caretreadmill trainingwalkerwearable device
项目摘要
Currently, progressive resistance exercise training, high intensity treadmill training, balanced-based
perturbation, and standard physical exercises are utilized to treat mobility deficits associated with PD;
however, the effectiveness of these therapies is limited. This study proposes to investigate the utility of a
portable exoskeleton for people with PD. The goal is to establish the safety of a lightweight portable
exoskeleton, the Keeogo, for gait training and to preliminarily assess its potential efficacy for gait mobility
and fall reduction. As the vast majority of PD patients eventually require assistive mobility devices, portable
exoskeletons represents an avenue for increased, mobility, quality of life, and independence. Robotic-assist
gait training (RAGT) has been extensively applied as a remarkable therapeutic modality, such that it is
enabling highly motivated people with devastating neurologic injuries to regain independent ambulation.
Despite the potential for this technology to transform the lives of people with PD, these devices are not
being adequately investigated in people with movement disorders.
To establish preliminary safety and efficiency of the Keeogo exoskeleton for PD patients at various disease
stages, we will examine representative subjects in Hohen & Yahr stages II, III, IV, and V. Inclusion criteria
are: 1) PD confirmed by a PADRECC movement disorder specialist using UK Brain Bank Criteria, 2)
Modified H&Y stage II-V. Exclusion criteria are: 1) neurological, musculoskeletal, or other disorders
unrelated to PD contributing to impairment of stance, gait, balance or coordination, 2) severe CHF, COPD,
or those requiring nasal canula O2, 3) history of implantable cardiac device or ablative surgery, 4) moderate
to severe cognitive impairment / dementia (Montreal Cognitive Assessment < 17/30), 5) symptomatic
orthostatic hypotension with exertion, 6) feeding tube or associated port placement (PEG/J-PEG), 7) body
height less than 5’1” or greater than 6’3” 8) body weight greater than 250 pounds, and 9) amputation of any
portion of the lower limbs. Subjects will participate in a total of 30 minutes RAGT ambulation with the Keeogo
twice per week for 6 weeks (12 sessions). Subjects may opt to utilize a platform rolling walker, rolling walker,
bilateral Lofstrand crutches or a unilateral device, such as a cane or Lofstrand crutch, and will be maintained
throughout the intervention.
To establish safety, the number and severity of AEs, such as falls, discomfort, skin or musculoskeletal
injury, and orthostatic hypotensive episodes will be documented. Intervention efficacy will be measured pre-
and post-donning of the Keeogo exoskeleton at bi-weekly intervention visits, and at a 6-week post-study
visit. Walking capacity, including benefits on FoG, will be assessed with the Six Minute Walk Test (6MWT),
balance and postural stability with the Berg Balance Scale (BBS), and disease severity with the
Examination, Part III, of the Unified Parkinson’s Disease Rating Scale (UPDRS). Additional assessments
will include Berg Balance Scale (BBS), ascending and descending stair climb, PDQ39, The University of
Alabama at Birmingham (UAB) Study of Aging Life-Space Assessment (LSA), and PD-Carer. As a primary
end point for establishing efficacy, the 6MWT will be compared between end of training and baseline (with
and without the exoskeleton), as well as at 6 and 12 weeks post-study as a durability assessment towards
establishing a need for future assessment of in-home usage. These pilot investigations are expected to lay
the groundwork for a large multi-center clinical study to establish ground exoskeletons as modern, standard
of care devices to aid Veterans and other people with PD and other disabling movement disorders to
maintain a more normal and productive life.
目前,渐进式阻力运动训练、高强度跑步机训练、平衡训练为主
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mark S Baron其他文献
Mark S Baron的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mark S Baron', 18)}}的其他基金
Advancement and Application of a Novel Basal Ganglia Thalamocortical Circuitry Model in Dystonia Rats
新型肌张力障碍大鼠基底节丘脑皮质环路模型的进展及应用
- 批准号:
10084214 - 财政年份:2011
- 资助金额:
-- - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
-- - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
-- - 项目类别: